Navigation Links
Scientists explain link between chlamydia and ectopic pregnancy
Date:1/11/2011

Women who have had chlamydia are at greater risk of an ectopic pregnancy because of a lasting effect of the infection.

A new study provides evidence for the first time of how chlamydia can increase the risk of an ectopic pregnancy which occurs when an embryo implants outside the womb, in the Fallopian tube.

Researchers at the University of Edinburgh found that women who had had the sexually transmitted infection were more likely to produce a particular protein in their Fallopian tubes.

Increased production of this protein known as PROKR2 makes a pregnancy more likely to implant in the Fallopian tube.

The study follows on from research, also at the University of Edinburgh, which showed that production of a similar protein increased the likelihood of smokers having an ectopic pregnancy.

Chlamydia is the most common sexually transmitted infection in the UK. It can be treated but often goes undiagnosed because it can occur without symptoms.

The infection is known to cause infertility as it can lead to scarring and blockages in the Fallopian tube.

This research shows, however, that chlamydial infection linked to ectopic pregnancy causes much more subtle changes in the Fallopian tube, without evidence of severe scarring.

The study, published in the American Journal of Pathology, was funded by the Wellbeing of Women and the Medical Research Council.

Dr Andrew Horne, of the University of Edinburgh's Centre for Reproductive Biology, said: "We know that chlamydia is a major risk factor for ectopic pregnancy but until now we were unsure how the infection led to implantation of a pregnancy in the Fallopian tube. We hope that this new information allows health care providers to give women accurate information about risks following chlamydial infection and to support public health messages about the importance of safer sex and chlamydia testing."


'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
44-131-650-9836
University of Edinburgh
Source:Eurekalert

Page: 1

Related medicine news :

1. Scientists shed light on what causes brain cell death in Parkinsons patients
2. VIB-K.U. Leuven scientists clear the way to alternative anti-angiogenic cancer therapy
3. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists
4. Scientists Aim for Test That Spots Single Cancer Cell in Blood Sample
5. Scientists Aim for Test That Could Spot Single Cancer Cell in Blood
6. Scientists Spot DNA Linked With Dangerous Heart Rhythms
7. Ion channel responsible for pain identified by UB neuroscientists
8. Scientists decode secrets of a very common virus that can cause cancer
9. Scientists Spot Genetic Areas Key to Embryonic Development
10. UNC scientists discover potential strategy to improve cancer vaccines
11. Scientists Raise Fat-Burning Levels in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... free of blood and protein soils where it ... Miele, the world’s leading manufacturer of premium domestic ... to verifying surgical instruments are effectively cleaned. The ... of surgical instruments immediately after processing. After 3 ...
(Date:7/29/2014)... is in principle suitable to find out which preferences ... it in health economic evaluations, some (primarily methodological) issues ... of a pilot project by the German Institute for ... Analytic Hierarchy Process (AHP), CA is the second method ... Summarize outcome-specific results to an overall value ...
(Date:7/29/2014)... new lung is grown for a patient in need, using ... injection of replacement cells will enable a patient to self-heal ... ALERT: For audio and video of Dr. Keller and Jorge ... Mayo Clinic News Network . , Regenerative ... gift from Jorge and Leslie Bacardi of the Bahamas will ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent S. Greenawalt ... (FCA) National Convention and Expo, speaking on Ground Force ... on Thursday, August 20th at the Hyatt Regency in ... impact functional foot orthotics, like Foot Levelers Stabilizing Orthotics, ... fasciitis, and hammertoes. , Invented by a chiropractor in ...
(Date:7/29/2014)... July 29, 2014 1WorldSync announces ... leading healthcare suppliers will utilize the Global Data ... information network to share product information with the ... trading partners across their global supply chain. Holger ... at B. Braun: "B. Braun serves customers in ...
Breaking Medicine News(10 mins):Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... say the drug clodronate is an effective treatment for patients ... studied more than 1,000 patients // with breast cancer. Patients ... day or a placebo for five years. ,Results showed ... to their bones. Fifty-one of these patients were treated with ...
... identified a protein that essentially blocks HIV replication, in ... is not as effective at stopping HIV, say the ... of Nature. The team, headed by Joseph Sodroski, is ... Infectious Diseases (NIAID). ,"Identification of this HIV-blocking ...
... According to recent findings researchers say the risks and ... to be re-evaluated.// Researchers from Sweden studied more than ... of age. Participants had their intellectual capacity tested at ... school attendance records for the young men. ,Results ...
... pressure at home may lead to fewer blood pressure ... at patients’ homes to conventional doctors’ office measurements of ... patients with a diastolic blood pressure reading of 95 ... offices were included for the study. All of the ...
... a new treatment can now help chronic chest pain sufferers ... other antianginal medications it was found to improve the total ... ,Ranolazine is currently under review by the FDA. ... angina were randomly assigned to receive a placebo or one ...
... a non-surgical technique used to eliminate alternate pathways ... // Researchers now say that congestive heart failure ... of irregular heart rhythm experience significant improvement ... catheter ablation. ,58 patients with congestive heart ...
Cached Medicine News:
(Date:7/29/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.476 ... or $(0.02) per share. These results compare to net ... $311 thousand, or $(0.04) per share, in the year-ago ...
(Date:7/28/2014)... , July 28, 2014 Pharmacyclics, Inc. (the "Company") ... hold a conference call and audio webcast to discuss financial ... Market closes on Thursday, July 31, 2014 at 4:30 p.m. ... Date: July 31, 2014 Time: 4:30 PM ... 303-7908 International: (678) 373-0875 A webcast replay will ...
(Date:7/28/2014)...  MiMedx Group, Inc. (NASDAQ: MDXG ), an integrated ... bioimplants processed from human amniotic membrane, announced today its results ... include: , Revenue exceeds upper end of ... million , Quarter-over-quarter revenue grew by ... 181% over Q2 2013 and 40% sequentially over Q1 2014 ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18
... Phase II Trial Initiated by Myriad For Azixa(TM), ... and OMX Nordic Exchange: EPCT) today reported on ... agent,licensed by the Company to Myriad Genetics, Inc. ... agreement. (Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) ...
... DNDN ) today announced publication of results ... active cellular immunotherapy, in the,August 20 issue of ... safety profile, immune response and clinical activity of ... failed standard,therapy. "In addition to demonstrating that ...
Cached Medicine Technology:EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 2EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 3EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 4EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 5Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4
... The new Guidant VASOVIEW® ... to deliver a new level ... harvesting for both the saphenous ... simultaneous cut-and-seal capability, it lets ...
...
... Now rapid intrapartum or antepartum GBS results ... versus 2 days. This revolutionary in vitro diagnostic ... designed to be run in the clinical lab ... and delivery nurses 24 hours a day, ...
... contains primers and a FAM-labeled probe that is ... the mecA gene. In addition, this ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
Medicine Products: